Expression of Bcl-2 and Ki-67 in tamoxifen-associated endometrial polyps: Comparison with postmenopausal polyps

被引:8
作者
Altaner, Semsi [1 ]
Gucer, Fatih
Tokatli, Fusun
Guresci, Servet
Ozdemir, Cigdem
Puyan, Fulya Oz
Kutlu, Kemal
机构
[1] Trakya Univ, Fac Med, Dept Pathol, Edirne, Turkey
[2] Anadolu Saglik Merkezi, Dept Obstet & Gynecol, Kocaeli, Turkey
[3] Trakya Univ, Fac Med, Dept Radiat Oncol, Edirne, Turkey
来源
ONKOLOGIE | 2006年 / 29卷 / 8-9期
关键词
polyps; endometrial; postmenopausal; tamoxifen; Bcl-2; Ki-67;
D O I
10.1159/000094443
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: The aim of this study was to evaluate the expression of Bcl-2 and Ki-67 in tamoxifen (TAM)-associated endometrial polyps and postmenopausal polyps. Material and Methods: For this purpose, a retrospective analysis of paraffin-embedded specimens was carried out. Polyps of 20 postmenopausal and 14 TAM-treated patients, 11 simple endometrial hyperplasia, 10 atypical complex endometrial hyperplasia and 8 endometrial adenocarcinoma specimens were included in the study. Hematoxylin/eosin-stained sections were evaluated. Immunohistochemical staining was performed to investigate the expression of Bcl-2 protein and the Ki-67 proliferation index. Results: There was no statistically significant difference between the 5 groups with regard to Bcl-2 staining (p > 0.05). However, Bcl-2 expression in TAM-associated polyps was higher (86%) than in the postmenopausal control group (80%). Positive Ki-67 was highest in the endometrial adenocarcinoma specimens, followed by the atypical complex endometrial hyperplasia group (p < 0.0001). Compared to these 2 groups, Ki-67 expression was lower in TAM-associated polyps, but Ki-67 indexes were significantly higher in the TAM-associated group than in the control group (p < 0.0001). Conclusion: Since TAM-associated polyps tend to have higher proliferation indexes and Ki-67 ratios than control groups, we suggest that they are likely to have a higher malignant potential.
引用
收藏
页码:376 / 380
页数:5
相关论文
共 21 条
[1]   Down-regulation of Bcl-2 is a potential marker of the efficacy of progestin therapy in the treatment of endometrial hyperplasia [J].
Amezcua, CA ;
Zheng, WX ;
Muderspach, LI ;
Felix, JC .
GYNECOLOGIC ONCOLOGY, 1999, 73 (01) :126-136
[2]  
[Anonymous], 1992, Lancet, V339, P1
[3]   Apoptosis in the endometrium [J].
Arends, MJ .
HISTOPATHOLOGY, 1999, 35 (02) :174-178
[4]   Uterine side effects of tamoxifen:: A need for systematic pretreatment screening [J].
Berlière, M ;
Charles, A ;
Galant, C ;
Donnez, J .
OBSTETRICS AND GYNECOLOGY, 1998, 91 (01) :40-44
[5]   Recurrent endometrial polyps in postmenopausal breast cancer patients on tamoxifen [J].
Biron-Shental, T ;
Tepper, R ;
Fishman, A ;
Shapira, J ;
Cohen, I .
GYNECOLOGIC ONCOLOGY, 2003, 90 (02) :382-386
[6]   Malignant endometrial polyps in postmenopausal breast cancer tamoxifen-treated patients [J].
Cohen, I ;
Bernheim, J ;
Azaria, R ;
Tepper, R ;
Sharony, R ;
Beyth, Y .
GYNECOLOGIC ONCOLOGY, 1999, 75 (01) :136-141
[7]   Endometrial pathologies associated with postmenopausal tamoxifen treatment [J].
Cohen, I .
GYNECOLOGIC ONCOLOGY, 2004, 94 (02) :256-266
[8]   Time-dependent effect of tamoxifen therapy on endometrial pathology in asymptomatic postmenopausal breast cancer patients [J].
Cohen, I ;
Altaras, MM ;
Shapira, J ;
Tepper, R ;
Rosen, DJD ;
Cordoba, M ;
Zalel, Y ;
Figer, A ;
Yigael, D ;
Beyth, Y .
INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY, 1996, 15 (02) :152-157
[9]   Postmenopausal endometrial pathologies with tamoxifen treatment: Comparison between hysteroscopic and hysterectomy findings [J].
Cohen, I ;
Azaria, R ;
Aviram, R ;
Bernheim, J ;
Tepper, R ;
Cordoba, M ;
Beyth, Y .
GYNECOLOGIC AND OBSTETRIC INVESTIGATION, 1999, 48 (03) :187-192
[10]   Significance of secondary ultrasonographic endometrial thickening in postmenopausal tamoxifen-treated women [J].
Cohen, I ;
Azaria, R ;
Shapira, J ;
Yigael, D ;
Tepper, R .
CANCER, 2002, 94 (12) :3101-3106